MATERIAL SAFETY DATA SHEET SECTION 1 - IDENTIFICATION OF PRODUCT AND COMPANY Pfizer Inc Emergency telephone Pfizer Animal Health Hours of operation 235 East 42nd Street Telephone New York, NY 10017 Trade names Temaril-P® Tablets Product name Temaril-P® Tablets Therapeutic use
Antitussive, Antipruritic, Antitussive, Anti-inflammatory
Description SECTION 2 - COMPOSITION
Ingredient(s) indicated as hazardous have been assessed under standardsfor workplace safety. SECTION 3 - HAZARDS IDENTIFICATION Signal word CAUTION! Statements of hazard MAY CAUSE NERVOUS SYSTEM EFFECTS. Eye effects
None known; however, direct contact with any foreign material may causeeye irritation. Skin effects Inhalation effects Ingestion effects
See 'Other potential health effects', below. Other potential health
This tablet contains material that can alter behavior, produce drowsiness,
muscle tremors or rigidity, stupor, or other nervous system effects. SECTION 3 - HAZARDS IDENTIFICATION . continued
This document has been prepared in accordance with standards forworkplace safety, which require the inclusion of all known hazards of theproduct or its ingredients regardless of the potential risk. Theprecautionary statements and warnings included may not apply in allcases. Your needs may vary depending upon the potential for exposure inyour workplace. SECTION 4 - FIRST AID MEASURES
Wash hands and arms thoroughly after handling this material. Obtainmedical assistance if skin effects occur.
Immediately flush eyes with water for at least 15 minutes. If irritationoccurs or persists, get medical attention.
Inhalation
Remove to fresh air. If not breathing, give artificial respiration. Ingestion
In the event of swallowing this material, seek immediate medical attention. Note to physician
Medical treatment in cases of overexposure should be treated as anoverdosage of phenothiazine. Refer to current prescribing information orto local poison control information centers. SECTION 5 - FIRE FIGHTING MEASURES General hazard
This mixture is expected to support combustion, based on componentspresent.Toxic or corrosive vapours are expected if this material is heated. Fire fighting instructions
Wear approved positive pressure, self-contained breathing apparatus andfull protective turn out gear. Move containers from fire area if possiblewithout increased personal risk. Dike area if possible to contain water forlater disposal.
Extinguishing media
Water, dry powder or foam extinguishers are recommended. Carbondioxide extinguishers may be ineffective.
Flash point Hazardous combustion
Toxic or corrosive gases are expected in fires involving this mixture. products SECTION 6 - ACCIDENTAL RELEASE MEASURES
Review Sections 3, 8 and 12 before proceeding with clean up. Small spill
Sweep spilled material into an approved container for disposal. Clean spillarea thoroughly. Prevent discharge to drains.
SECTION 6 - ACCIDENTAL RELEASE MEASURES . continued Large spill
Contain the source of the spill or leak if it is safe to do so. Scoop or shovelspilled material into a labeled container for disposal. Clean spill areathoroughly. Prevent discharge to drains.
SECTION 7 - HANDLING AND STORAGE General handling
IF TABLETS OR CAPSULES ARE CRUSHED AND/OR BROKEN,AVOID BREATHING DUST AND AVOID CONTACT WITH EYES,SKIN AND CLOTHING. Storageconditions
Avoid prolonged storage at elevated temperatures (greater than roomtemperature, approximately 20 degrees C). Keep in tightly closedcontainers or packages away from moisture. SECTION 8 - EXPOSURE CONTROLS/PERSONAL PROTECTION Ventilation
Good general ventilation should be sufficient to control airborne levels. Respiratory protection
Respirators are not required for normal use of this material. Eye protection
Not required under normal conditions of use. Skin protection
None required for the normal use of this material. Wash hands and armsthoroughly after handling this material. Clean up spills immediately. Hand protection
Not required for the normal use of this material. SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES Physical form Molecular weight Molecular formula Boiling point Melting point Vapor pressure Water solubility Solvent solubility SECTION 10 - STABILITY AND REACTIVITY Reactivity Conditions to avoid
Direct sunlight, conditions that might generate heat and dispersion as adust cloud
Incompatibilities Hazardous decomposition products Hazardous polymerization Explosive properties
Not identified. As with many organic dusts, explosions might result whenexcessive dust concentrations are present.
SECTION 11 - TOXICOLOGY INFORMATION Acute toxicity Inhalation
Not applicable for solid, finished formulations.
Ingestion
The calculated LD50 is less than 2000 mg/kg, based on effects ofindividual components and concentrations present. Mutagenicity Subchronic effects Chronic effects/ carcinogenicity Carcinogen status
None of the components of this formulation is listed as a carcinogen byIARC, NTP or OSHA.
Reproductive effects Teratogenicity At increased risk from
Depressant effects of some medications or alcohol.
exposure Additional information
This material contains a phenothiazine tranquiliser.
SECTION 12 - ECOLOGICAL INFORMATION Environmental overview
The environmental characteristics of this mixture have not been fullyevaluated. Releases to the environment should be avoided. SECTION 13 - DISPOSAL INFORMATION Disposal procedure
Collect for recycling or recovery, if possible. Dispose of material on sitein a licensed chemical incinerator, if allowed by the incinerator license orpermit. If no on-site incinerator is available, dispose of material in alicensed commercial chemical incinerator.
SECTION 14 - TRANSPORTATION INFORMATION General shipping
Not regulated for transport under USDOT, EUADR, IATA, or IMDG
instructions SECTION 15 - REGULATORY INFORMATION EU Classification EU Labelling EU Label Pictogram(s) Safety phrases Canadian WHMIS
This product has been classified in accordance with the hazard criteria ofthe CPR and the MSDS contains all of the information required by theCPR. SECTION 16 - OTHER Disclaimer Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without a warranty of any kind, expressed or implied.
1. LEGEMIDLETS NAVN 2. KVALITATIV OG KVANTITATIV SAMMENSETNING 1 tablett inneholder:Haloperidol 1 mg. Haloperidol 4 mg. For fullstendig liste over hjelpestoffer se pkt. 6.1. 3. LEGEMIDDELFORM Tabletter. 1 mg tabletter: Hvite, runde, bikonvekse med delekors preget med ”JANSSEN” på den ene siden. 4 mg tabletter: Hvite, runde, bikonvekse med delekors preget med ”JANSSEN” på de
US sonography in renal transplant: what role? Our experience in recent years, together with the literature of the same period, allows us to state that, from the early seventies (1), when our radiology colleagues were the first to undertake the US study of renal transplant, to these days, the technology has undergone fascinating developments and US has, at the same time, experienced a sort of “